AcetoacetanilideCAS# 102-01-2 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 102-01-2 | SDF | Download SDF |
| PubChem ID | 7592 | Appearance | Powder |
| Formula | C10H11NO2 | M.Wt | 177 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 3-oxo-N-phenylbutanamide | ||
| SMILES | CC(=O)CC(=O)NC1=CC=CC=C1 | ||
| Standard InChIKey | DYRDKSSFIWVSNM-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C10H11NO2/c1-8(12)7-10(13)11-9-5-3-2-4-6-9/h2-6H,7H2,1H3,(H,11,13) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Acetoacetanilide Dilution Calculator
Acetoacetanilide Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 5.6497 mL | 28.2486 mL | 56.4972 mL | 112.9944 mL | 141.2429 mL |
| 5 mM | 1.1299 mL | 5.6497 mL | 11.2994 mL | 22.5989 mL | 28.2486 mL |
| 10 mM | 0.565 mL | 2.8249 mL | 5.6497 mL | 11.2994 mL | 14.1243 mL |
| 50 mM | 0.113 mL | 0.565 mL | 1.1299 mL | 2.2599 mL | 2.8249 mL |
| 100 mM | 0.0565 mL | 0.2825 mL | 0.565 mL | 1.1299 mL | 1.4124 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- GW791343 dihydrochloride
Catalog No.:BCC1613
CAS No.:1019779-04-4
- Zardaverine
Catalog No.:BCC2069
CAS No.:101975-10-4
- Octacosyl (E)-ferulate
Catalog No.:BCN5834
CAS No.:101959-37-9
- S0859
Catalog No.:BCC1914
CAS No.:1019331-10-2
- Calyculin A
Catalog No.:BCC2457
CAS No.:101932-71-2
- Regorafenib monohydrate
Catalog No.:BCC1884
CAS No.:1019206-88-2
- Dabigatran etexilate benzenesulfonate
Catalog No.:BCC8925
CAS No.:1019206-65-5
- sodium 4-pentynoate
Catalog No.:BCC1958
CAS No.:101917-30-0
- LX-4211
Catalog No.:BCC1714
CAS No.:1018899-04-1
- 7-Z-Trifostigmanoside I
Catalog No.:BCN7869
CAS No.:1018898-17-3
- Diclazuril
Catalog No.:BCC8937
CAS No.:101831-37-2
- Butenafine HCl
Catalog No.:BCC4768
CAS No.:101827-46-7
- 3,4-Dihydroxyphenylacetic Acid
Catalog No.:BCC8281
CAS No.:102-32-9
- Phenyethyl 3-methylcaffeate
Catalog No.:BCN8457
CAS No.:71835-85-3
- Sulfaclozine
Catalog No.:BCC9155
CAS No.:102-65-8
- 20,24-Epoxy-24-methoxy-23(24-25)abeo-dammaran-3-one
Catalog No.:BCN1639
CAS No.:1020074-97-8
- SGI-1027
Catalog No.:BCC4588
CAS No.:1020149-73-8
- DCC-2036 (Rebastinib)
Catalog No.:BCC4390
CAS No.:1020172-07-9
- (R)-4-Benzyl-2-oxazolidinone
Catalog No.:BCC8395
CAS No.:102029-44-7
- PF-04457845
Catalog No.:BCC1851
CAS No.:1020315-31-4
- Protosappanin A
Catalog No.:BCN7259
CAS No.:102036-28-2
- Protosappanin B
Catalog No.:BCN2281
CAS No.:102036-29-3
- Tubeimoside I
Catalog No.:BCN1089
CAS No.:102040-03-9
- 3-Deazaneplanocin,DZNep
Catalog No.:BCC1129
CAS No.:102052-95-9
Cytotoxic and Antitumour Studies of Acetoacetanilide N(4)-methyl(phenyl)thiosemicarbazone and its Transition Metal Complexes.[Pubmed:26997691]
Indian J Pharm Sci. 2015 Nov-Dec;77(6):655-60.
Cytotoxic activities of Acetoacetanilide N(4)-methyl(phenyl)thiosemicarbazone (L2H) and its seven different metal complexes were studied. Of these, IC50 value of the copper complex was found to be 46 mug/ml. Antitumour studies of this copper complex was carried out using Daltons Lymphoma Ascites cell-induced solid tumour model and Ehrlich's Ascites Carcinoma cell-induced ascites tumour model. Administration of the copper complex at different concentrations (10, 5 and 1 mg/kg b. wt) inhibited the solid tumour development in mice and increased the mean survival rate and the life span of Ascites tumour bearing mice in a concentration dependent manner.
Multicomponent Reactions of Acetoacetanilide Derivatives with Aromatic Aldehydes and Cyanomethylene Reagents to Produce 4H-Pyran and 1,4-Dihydropyridine Derivatives with Antitumor Activities.[Pubmed:26633027]
Chem Pharm Bull (Tokyo). 2015;63(12):1055-64.
The multi-component reaction of either Acetoacetanilide derivative 1a or b with any of the aldehyde derivatives 2a-d and malononitrile 3 in the presence of triethylamine as a catalyst gave the 4H-pyran derivatives 4a-g, respectively. Carrying the same reaction but using a catalytic amount of ammonium acetate gave the 1,4-dihydropyridine derivatives 5a-f, respectively. The use of ethyl cyanoacetate instead of malononitrile in the presence of a catalytic amount of triethylamine gave the 4H-pyran derivatives 7a-d, respectively. Compound 4e was used to synthesize 1,4-dihydropyridine 9a-c and arylhydraone 11a-e derivatives were synthesized from 4a and e. The anti-tumor evaluations of the newly synthesized products were tested against six human cancer and normal cell lines. The results showed that compounds 4a, b, f, 5d, f, 9 and 11a-d had optimal cytotoxic effect against cancer cell lines with IC50<550 nM. The toxicity of the most active compounds was further measured against shrimp larvae.
